

# Metallomics

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Title

**Inclusion bodies and pH lowering: as an effect of gold nanoparticles in *Streptococcus pneumoniae*.**

Author names

**Edgar Augusto Ortiz-Benítez<sup>1</sup>, Mariana Carrillo-Morales<sup>1</sup>, Norma Velázquez-Guadarrama<sup>2</sup> Jesús Fandiño-Armas<sup>1</sup> and José de Jesús Olivares-Trejo<sup>1\*</sup>**

Corresponding author e-mail address

**\*Corresponding author e-mail address: [olivarestrejo@yahoo.com](mailto:olivarestrejo@yahoo.com)**

**<sup>1</sup>Posgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México**

**San Lorenzo 290, C.P. 03100, Ciudad de México**

**Tel.+525554886661 ext 15309**

**<sup>2</sup>Laboratorio de Bacteriología, Hospital Infantil de México, Federico Gomez, Ciudad de México, México**

## **Abstract**

*Streptococcus pneumoniae* is a human pathogen whose principal virulence factor is its capsule. This structure allows the bacteria to evade the human immune system. The treatment of infections caused by this bacterium is based on antibiotics, however the emergence of antibiotic resistant strains makes this task increasingly difficult. Therefore, is necessary to investigate new therapies such as those based on gold nanoparticles; unfortunately the mechanisms involved have not been investigated yet. As far as we know, this study is the first approach, which attempt to explain how gold nanoparticles destroy the bacterium *Streptococcus pneumoniae*. We found that the particle mean size was an important issue, and the effect on the bacteria was dose-dependent. The cellular growth was inhibited by the presence of the nanoparticles, and also the viability. The pH of the media was acidified, but interestingly the reactive species were not affected. The analysis of transmission electron microscopy, revealed a inclusion bodies of gold

1  
2  
3 nanoparticles the bacteria composed by nanoparticles. We presented the first  
4 findings that attempt to explain how gold nanoparticles lyse the Gram positive  
5 bacteria.  
6  
7  
8  
9

10  
11  
12 **Keywords:** *Streptococcus pneumoniae*; AuNPs; Antibacterial properties; Capsule;  
13 Reactive oxygen species; inclusion bodies of gold nanoparticles.  
14  
15  
16  
17  
18  
19

## 20 Introduction

21  
22 *Streptococcus pneumoniae* is an encapsulated Gram positive coccus bacterium,  
23 that is spherical in shape with diameters between 1-2  $\mu\text{m}$  termed coccus.<sup>1</sup> *S.*  
24 *pneumoniae* is common in the respiratory tract of human.<sup>2-4</sup> This bacterium is an  
25 opportunist pathogen which infects nasopharynx and lung, causing sinusitis or  
26 pneumonia. This coccus can reach the blood system and could produce  
27 septicaemia that is lethal whether is not treated properly.<sup>5</sup> The successful  
28 invasiveness of this bacterium is mainly due to the capsule.<sup>6-9</sup> In fact this structure,  
29 mainly composed by carbohydrates, is considered one of the most important  
30 virulence factors developed by this pathogen because it allows *S. pneumoniae* to  
31 evade the immune system of the host.<sup>10-12</sup> Antibiotics such as penicillin,  
32 erythromycin, cephalosporins, rifampin, vancomycin and trimethoprim-  
33 sulfamethoxazole are the mainstay treatment for infections caused by *S.*  
34 *pneumoniae*.<sup>13-15</sup> Until the 1970s all the isolates were sensitive to antibiotics,  
35 however, in the 1990s the sensitivity diminished by a considerable amount.  
36  
37 Therefore, is imperative to find new therapies for the treatment of infections caused  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 by this pathogen, a good alternative for this purpose, could be the usage of gold  
4 nanoparticles (AuNPs). AuNPs have shown a good antibacterial effect when they  
5 are tested in growth media.<sup>16,17</sup> *Escherichia coli*,<sup>18</sup> *Staphylococcus aureus*,  
6  
7  
8 *Citrobacter koseri*, *Bacillus cereus*, *Pseudomonas aeruginosa*,<sup>19</sup> *Bacillus subtilis*,  
9  
10  
11 *Klebsiella pneumoniae*,<sup>20</sup> *Salmonella typhi*,<sup>21</sup> all of them are bacteria, which are  
12  
13  
14 sensible to the presence of AuNPs in the cellular growth. The average diameter of  
15  
16  
17 the AuNPs, which has been tested is between 5-50 nm.<sup>22-24</sup> Nevertheless, the  
18  
19  
20 major effectiveness was observed with sizes around 20 nm.<sup>25,26</sup> The minimal  
21  
22  
23 inhibitory concentration (MIC) is 2,500 µg/ml with a size of 13 nm Fe<sub>3</sub>O<sub>4</sub>@Au for  
24  
25  
26 *Pseudomonas aeruginosa*<sup>19</sup> and 5,000 µg /ml with a size of 22 nm AuNPs for *E.*  
27  
28  
29 *coli* showing better antibacterial activity for Gram positive than Gram negative  
30  
31  
32 bacteria.<sup>27</sup> One advantage of using AuNPs is the fine-tuning antimicrobial profile  
33  
34  
35 because the surface of AuNPs can be functionalized sequentially using  
36  
37  
38 polyoxometalates and lysine.<sup>28</sup> In fact the nanoparticles can be functionalized with  
39  
40  
41 antibodies against a specific target in order to diminished the effective antibacterial  
42  
43  
44 concentration. The mechanism by which the AuNPs destroy the bacteria is not  
45  
46  
47 clear yet, however, several mechanisms have been proposed, for instance, in *E.*  
48  
49  
50 *coli* the AuNPs could bind to the bacterial membrane, causing a collapse in its  
51  
52  
53 potential, then, the ATPase activity is inhibited and therefore the ATP levels  
54  
55  
56 decrease. Interestingly, in these experiments reactive oxygen species (ROS) were  
57  
58  
59 not detected.<sup>16,29,30</sup> Another mechanism proposed is the alteration of pH. It has  
60  
61  
62 been suggested that the NPs could modify the pH of bacterial environment in such  
63  
64  
65 a way that when the pH is acidified the environment becomes toxic for bacteria.<sup>31</sup>  
66  
67  
68 Additionally the intracellular pH could be modified as well.<sup>32</sup> All these mechanisms

1  
2  
3 have been proposed for *E. coli*, a bacilli Gram negative without capsule.  
4  
5 Nonetheless, for *S. pneumoniae*, a Gram positive encapsulated pathogen, the  
6  
7 mechanism has not been investigated yet. In the present study we attempt to  
8  
9 investigate whether the antibacterial properties of the AuNPs inhibit the cellular  
10  
11 growth of a bacterium whose principal virulence factor is the capsule. Therefore,  
12  
13 the AuNPs effect is analysed in a mutant bacterium (non-capsulated), which is  
14  
15 compared with the wild type bacterium (capsulated).  
16  
17  
18  
19  
20  
21

## 22 **Experimental**

### 23 **Cellular cultures**

24  
25 *S. pneumoniae* R6 (ATCC BAA-255) and TIGR4 (ATCC BAA-334) strains were  
26  
27 cultivated for 18 h, at 37°C and 10% CO<sub>2</sub> on Todd Hewitt agar. There after,  
28  
29 bacteria were inoculated in Todd Hewitt broth supplemented with 0.5% of yeast  
30  
31 extract and incubated for 18 h 10% CO<sub>2</sub> at 37° C.  
32  
33  
34  
35  
36  
37  
38

### 39 **Gold nanoparticles synthesis (AuNPs)**

40  
41 Gold nanoparticles were synthesized using 10 ml of 1 mM chloroauric acid  
42  
43 (HAuCl<sub>4</sub>) were boiled. When the ebullition temperature was reached, 18 ml of  
44  
45 38.88 M sodium citrate dehydrated (HOC(COONa)(CH<sub>2</sub>COONa)<sub>2</sub> · 2H<sub>2</sub>O) were  
46  
47 added and the mix was boiled for 15 min. Thus, the solution was maintained at  
48  
49 room temperature for 2 h. Three washes with water milliQ (centrifuging at 23,143 x  
50  
51 g) were performed in order to eliminate traces of HAuCl<sub>4</sub> and citrate. After that, gold  
52  
53 nanoparticles were covered with polyethylene glycol (PEG, Molecular weight  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 3,400). 0.5 mg/ml were mixed with in a shaking grate. The mix was maintained in  
4  
5 agitation for 2 h at room temperature and washed with water (milliQ) and  
6  
7 centrifuged (23,143 x g)<sup>33</sup>. In order to corroborate the results all the experiments  
8  
9 were performed using nanoparticles (20 nm) purchased from Sigma (catalog  
10  
11 number 765716) obtaining also similar results.  
12  
13  
14  
15

### 16 17 **Determination of the weight**

18  
19 In order to determine the yield after synthesis, empty tubes were weighed. Then 1  
20  
21 ml of AuNPs pegylated was added and centrifuged at 23,143 x g, the supernatant  
22  
23 was eliminated and tubes were dried for 3 days at room temperature, and they  
24  
25 were weighed again to obtain the dry weight. All the experiments were performed  
26  
27 by triplicate in three occasions.  
28  
29  
30  
31  
32  
33

### 34 **Inhibition of cellular growth**

35  
36 In order to investigate the inhibition of cellular growth, the bacteria (R6, avirulent)<sup>34</sup>  
37  
38 and TIGR 4 (virulent serotype 4)<sup>35</sup> were cultivated in Mueller-hinton media  
39  
40 supplemented with 5% sheep blood, then the optical density was adjust to 0.5.  
41  
42 After that, 100 µl of AuNPs were added. The concentration tested (20 nm ± 0.9)  
43  
44 were 1024, 512, 256 and 128 µg/ml. Thereafter, the bacteria cultures were  
45  
46 incubated at 37° C and 10% CO<sub>2</sub>. Cellular growth was determined each hour by  
47  
48 spectrophotometry at 600 nm.  
49  
50  
51  
52  
53  
54

### 55 **Transmission electronic microscopy (TEM)**

56  
57  
58  
59  
60

1  
2  
3 Bacteria were cultivated in Todd Hewitt broth and were tested with  $(20 \pm 0.9 \text{ nm})$   
4  
5 512  $\mu\text{g/ml}$  of AuNPs. Media growth was eliminated by centrifugation at  $7000 \times g$  for  
6  
7 10 min. Bacteria were fixed with 2% formaldehyde for 1 h. A washed was  
8  
9 performed with PBS buffer (10 mM). Then, samples were fixed with a pH 7.3 buffer  
10  
11 solution containing 2.5% glutaraldehyde and 4% formaldehyde. Three washes  
12  
13 were performed with PBS solution at room temperature for 5 min. After that, the  
14  
15 contrast was performed for 1.5 h using a mix of 2% osmium tetroxide and 4%  
16  
17 uranyl acetate (1:1). Thus three washes were performed with PBS. Samples were  
18  
19 dehydrated with ethanol using concentrations of 30, 50, 70, 80 and 96% changing  
20  
21 each 15 min and 2 changes with ethanol absolute for 30 min were performed.  
22  
23 These samples were tested with propylen oxide in two occasions for 30 min. The  
24  
25 slides were performed in a propylen oxide-resin (1:1) for 5 h (1:2) overnight,  
26  
27 thereafter epoxy resin was added at  $60^\circ \text{C}$  for 24 h. The TEM observation was  
28  
29 performed at 60 and 80 KV.  
30  
31  
32  
33  
34  
35  
36  
37  
38

### 39 **Determination of pH in the bacterial culture**

40  
41 To determine the pH during the incubation of *S. pneumoniae* with AuNPs, the  
42  
43 bacteria was cultivated in 10 ml of Todd Hewitt broth until reach 0.5 of optical  
44  
45 density at 600 nm. Then, 1024, 512 and 256  $\mu\text{g/ml}$  AuNPs were added, creating  
46  
47 different batches and the pH was determined each hour using a pH meter. As a  
48  
49 control: Todd Hewitt broth with or without AuNPs, bacteria without AuNPs. All the  
50  
51 conditions tested were incubated at  $37^\circ \text{C}$ , 10%  $\text{CO}_2$ . The pH was determined each  
52  
53  
54  
55 h.  
56  
57  
58  
59  
60

### Reactive oxygen species

Free radicals were determined using the Red hydrogen peroxide assay kit for microplates ENZO. A standard curve was prepared using 3.33, 1.11, 0.37, 0.12, 0.04, 0.01  $\mu\text{M}$   $\text{H}_2\text{O}_2$ , which were performed by serial dilutions of a stock solution 10  $\mu\text{M}$   $\text{H}_2\text{O}_2$ . Samples were tested in the same way and all were determined by spectrophotometry at 576 nm.

## Results

### Gold nanoparticles synthesized (AuNPs) are spherical

In order to obtain the gold nanoparticles system used throughout this study, we performed several synthesis based on the well-known Turkevich method.<sup>33</sup> This protocol allows us to obtain near spherical AuNPs with good control over their average diameters. Sets of different sizes were tested in a previous experiment, where the best results were obtained with nanoparticles of  $20 \pm 0.9$  nm. For that reason all the subsequent experiments were performed using nanoparticles of this size (Fig. 1).

### AuNPs has antibacterial properties over capsulated bacteria

AuNPs have shown a good antibacterial activity when they are tested in Gram negative bacteria however, the mechanism responsible for that behaviour is poorly understood. In fact, for pathogen bacteria such as *S. pneumoniae* (an encapsulated pathogen) the antibacterial properties of AuNPs remain unknown. In order to investigate the antibacterial properties of this nanoparticles, the bacterium *S. pneumoniae* was growth in Todd Hewitt broth. When the bacterial culture



1  
2  
3 reached an optical density (at 595 nm) of 0.15, different concentrations of AuNPs  
4 ranging from 128 up to 1024  $\mu\text{g/ml}$  were added. All the bacterial cultures were  
5 followed for 22 h taking samples each 2 h. The inhibitory effect observed was  
6 dose-dependent, because the major effect is observed with concentrations of 1024  
7 ( $\bullet$ ) or 512  $\mu\text{g}$  of AuNPs ( $\blacksquare$ ) (Fig. 2). The concentrations of 256 ( $\blacktriangle$ ), or 128 ( $\blacktriangledown$ )  
8 showed a result close to that of the control (without AuNPs) ( $\blacklozenge$ ) (Fig. 2).  
9 Surprisingly, the antibacterial effect was similar for both *S. pneumoniae* TIGR4  
10 strain (wild type) (Fig. 2B) and *S. pneumoniae* R6 strain (a mutant non-capsulated)  
11 (Fig. 2A). This result shows that the AuNPs have antibacterial properties over  
12 bacteria regardless they are capsulated or not.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **AuNPs inhibits the viability of *S. pneumoniae***

30  
31 The fact that AuNPs inhibited the cellular growth of *S. pneumoniae* suggests that  
32 AuNPs could affect the viability. In order to explore this assumption, *S.*  
33 *pneumoniae* was growth in Todd Hewitt broth and concentrations of 256, 512 and  
34 1024  $\mu\text{g/ml}$  were added. Samples were collected each 2 h and the viability was  
35 determined. The results show that the viability was affected when the Todd Hewitt  
36 broth was supplemented with 512 and 1024  $\mu\text{g/ml}$  of AuNPs (Fig. 3). These results  
37 clearly show that the AuNPs inhibit the cellular growth and the viability of *S.*  
38 *pneumoniae*.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

### 53 **AuNPs diminished the extracellular pH of *S. pneumoniae***

1  
2  
3 Since AuNPs inhibited the cellular growth and the viability, we decided to  
4 investigate the molecular mechanism behind this effect. As it was previously  
5 mentioned, one of the mechanisms proposed in the literature for antibacterial effect  
6 of nanoparticles was the lowering in pH values. In order to explore this assumption,  
7 the pH of the culture media was determined during the cellular growth of *S.*  
8 *pneumoniae*. The results clearly show that the pH was acidified for more than 1  
9 unit when AuNPs were added (Fig. 4). At the beginning of the experiment the pH  
10 was 8.8 and after 11 h of cultivation it dropped up to 7.2. The controls tested Todd  
11 Hewitt broth, inoculated or not, showed an acidification of only 0.4 units of pH. In  
12 order to investigate whether or not the acidification is due to bacterial lysis, we  
13 determined the pH during the cellular growth, previous to bacterial lysis induced by  
14 sonication without AuNPs (Fig. 4). This control showed a pH of 8.7 after 11 h of  
15 incubation without nanoparticles (Fig. 4). Our overall results, show that the  
16 acidification observed is due to the presence of AuNPs in the media and perhaps it  
17 helps to destroy the bacteria.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

#### 41 **AuNPs did not modify the reactive oxygen species (ROS) yielded by**

#### 42 ***S. pneumoniae***

43  
44 The acidification of the extracellular media was established as an effect related to  
45 the addition of AuNP's to the culture media. We also searched for a variation in  
46 other relevant parameters such us ROS. *S. pneumoniae* was cultivated in Todd  
47 Hewitt broth supplemented with AuNPs, samples were taken each hour, and the  
48 ROS were quantified by ENZO kit. The results did not show any important increase  
49 in the ROS production when *S. pneumoniae* was cultivated in presence of 512  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  $\mu\text{g/ml}$  AuNPs in comparison with the strains without nanoparticles (Fig. 5). These  
4  
5 results suggest that the presence of AuNPs does not change the reactive oxygen  
6  
7 species in the culture media.  
8  
9

### 10 11 12 **AuNPs crosses the capsule of *S. pneumoniae***

13  
14 The acidification of growth media caused by AuNPs, could be by direct contact of  
15  
16 AuNPs with the bacterium. In order to explore more, the bacterium *S. pneumoniae*  
17  
18 previously cultivated for 3 h in presence of AuNPs, was observed by TEM and  
19  
20 several slices were performed. At the beginning the nanoparticles are observed  
21  
22 surrounding the bacterium (Fig. 6B). Then the nanoparticles are grouped in a  
23  
24 specific point of the bacterium (Fig. 6C), and later they are introduced into the cell,  
25  
26 forming a structure termed by us inclusion bodies of gold nanoparticles (Fig. 6D),  
27  
28 Finally, cells are lysed (Fig. 6E). Same results were obtained when the  
29  
30 experiments were performed with TIRG 4 (a capsulated strain) (Fig. 6A', B', C', D'  
31  
32 and E'). We believe that those inclusion bodies of gold nanoparticles are  
33  
34 composed for a membrane because it has a spherical form whose size is close to  
35  
36 130 nm. Our overall results show that the AuNPs have an antibacterial effect, able  
37  
38 to abate the viability of *S. pneumoniae*, in which, the nanoparticle can cross the  
39  
40 capsule membrane, cellular wall, reaching the cytoplasm, in a structure composed  
41  
42 perhaps by lipids. When this mechanism occurs, several cellular processes are  
43  
44 modified, producing acidification of the extracellular environment and finally leading  
45  
46 to cellular death.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

AuNPs have a great potential as antibacterial agent, some of their properties have been studied in Gram negative bacteria such as *E. coli*. However, for many Gram positive bacteria, their effect is practically unknown. In fact, *S. pneumoniae* is a pathogen in which the antibacterial effect of AuNPs, have not been previously investigated. In this work, we study the antibacterial effect of AuNPs in *S. pneumoniae*. We present TEM images showing the ability of the nanovehicles to traverse the capsule in the TIGR 4 strain, this capsule helps *S. pneumoniae* to evade the immune system of the host. The methodology used to obtain AuNPs allows us to obtain a size of 20 nm, which showed an excellent antibacterial effect, this result was in agreement with some other studies found in the literature for *E. coli* where the optimum size of nanoparticles was the same diameter.<sup>36,37</sup> The antibacterial effect of AuNPs also was dose-dependent, because, when nanoparticles concentration was increased up to 512 or 1024  $\mu\text{g/ml}$ , the cellular growth was abated. The cellular death was corroborated by determination of the viability, which decreased in presence of AuNPs, in opposition with the controls in which, the units forming colony (CFU) were  $1 \times 10^5$ . These results clearly showed that AuNPs are an excellent alternative to eliminate *S. pneumoniae*. The presence of nanoparticles no increased the ROS levels indicating that AuNPs kill to *S. pneumoniae* by a mechanism different from ROS production. The cellular death of *S. pneumoniae* could be related to a decrement in pH values, Perhaps, the increasing of  $\text{H}^+$  destabilizes the membrane and the capsule of this pathogen, forming pores that allow AuNPs to enter. TEM images displayed different moments

1  
2  
3 of AuNP's interaction with the bacteria and could lead to a possible explanation of  
4 the underlying mechanism. We believe that the bacteria could attract the AuNPs,  
5 by electrostatic forces, thereafter, the NPs bind the bacterium and later they are  
6 internalised into the cytoplasm via a structure termed inclusion bodies of gold  
7 nanoparticles composed principally by lipids and/or carbohydrates, because, the  
8 structure is spherical. In the bacteria this structure induces damage and finally the  
9 bacterium is lysed. In conclusion our findings attempt to explain the mechanism by  
10 which the AuNPs inhibit the cellular growth and the viability of *S. pneumoniae*. This  
11 mechanism is based in pH lowering and formation of inclusion bodies. We believe  
12 that these studies are necessary because in the future nanotechnology is  
13 visualized as an alternative therapy to the use of antibiotics therefore we need  
14 known the mechanism of gold nanoparticles.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

### 34 **Acknowledgments**

35  
36 This work was supported by CONACyT (Consejo Nacional de Ciencia y  
37 Tecnología) (grant numbers SALUD-2010-01-139945, SALUD-2012-01-181641).

38  
39 We thank Biologist Alejandra Stephany Rodríguez Leviz from Hospital Infantil de  
40 México Federico Gómez for her excellent technical support to operate TEM.  
41  
42  
43  
44  
45  
46  
47

### 48 **Figure legends**

49  
50  
51  
52  
53 **Fig. 1** Transmission Electron Microscopy (TEM) of AuNPs.

54  
55 The AuNPs reached an average size of 20 nm  $\pm$  0.9.  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 **Fig. 2** AuNPs inhibit the cellular growth at concentrations of 512 and 1024 µg/ml.

6  
7 R6 (A) and TIGR (B) strains were cultivated until reach an optical density of  
8 approximately 0.2. There after the AuNPs were added at concentrations of 128,  
9 256, 512 and 1024 µg/ml, then the optical density was measured each 2 h in order  
10 to determine the cellular growth.  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 **Fig. 3** AuNPs inhibit the viability at concentrations of 512 and 1024 µg/ml.

21 R6 (A) and TIGR (B) strains were cultivated until reach an optical density  
22 approximately of 0.2. Thereafter the AuNPs were added at concentrations of 128,  
23 256, 512 and 1024 µg/ml, then the CFU were calculated each 2 h in order to  
24 determine viability.  
25  
26  
27  
28  
29  
30  
31  
32  
33

34 **Fig. 4** AuNPs diminished the pH in the culture media. R6 (A) and TIGR (B) strains  
35 were cultivated until reach an optical density of approximately 0.2. There after the  
36 AuNPs were added at concentrations of 512 and 1024 µg/ml, then the pH was  
37 measured each hour.  
38  
39  
40  
41  
42  
43  
44  
45

46 **Fig. 5** AuNPs did not modified the production of ROS of *S. pneumoniae* in the  
47 culture media. R6 (A) and TIGR (B) strains were cultivated until reach an optical  
48 density of approximately 0.2. Thereafter the AuNPs were added at a concentration  
49 of 1024 µg/ml, then samples were collected each hour, in order to determine ROS.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Fig. 6** AuNPs cross the capsule in in a TIGR strain. R6 without capsule (A) and  
4  
5 TIGR with capsule (B) strains were cultivated until reach an optical density of  
6  
7 approximately 0.2. Thereafter the AuNPs were added at a concentration of 1024  
8  
9  $\mu\text{g/ml}$ , samples were taken at 0.5, 1, 2 and 3 h in order to observe the effect by  
10  
11 TEM.  
12  
13  
14  
15  
16  
17

## 18 Reference list

- 19  
20  
21 1. Ryan K. and Ray G. (2004.). Sherris Medical Microbiology: An Introduction to  
22  
23 Infectious Disease. (Fourth Edition. ed.). New York.: McGraw-Hill.  
24  
25
- 26  
27 2. Balakrishnan, I., Crook, P., Morris, R. & Gillespie, S. H. (2000). Early predictors  
28  
29 of mortality in pneumococcal bacteraemia. J. Infect. Dis. 40, 256–261.  
30  
31
- 32  
33 3. Zhang J., Mostov K., Lamm M., Nanno M., Shimida S., Ohwaki M. and  
34  
35 Tuomanen E. (2000). The polymeric immunoglobulin receptor translocates  
36  
37 pneumococci across human nasopharyngeal epithelial cells. Cell 102(6):827–837.  
38  
39
- 40  
41 4. Nelson A., Ries J., Bagnoli F., Dahlberg S., Falker S., Rounioja S., Tschop J.,  
42  
43 Morfeldt E., Ferlenghi I., Hilleringmann M., Molden D., Rappuoli R., Normark S.,  
44  
45 Barocchi M. and Henriques-Normark B. (2007). RrgA is a pilus-associated adhesin  
46  
47 in *Streptococcus pneumoniae*. Mol. Microbiol. 66(2):329–340.  
48  
49
- 50  
51 5. Tuomanen E., Austrian R. and Masure R. (1995). Pathogenesis of  
52  
53 Pneumococcal Infection. N. Engl. J. Med. 332:1280-1284.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 6.Briles D., Crain M., Gray B., Forman C. and Yother J. (1992). Strong association  
4 between capsular type and virulence for mice among human isolates of  
5  
6 *Streptococcus pneumoniae*. Infect. Immun. 60(1):111.  
7  
8

9  
10  
11 7. Austrian R. (1981) Some observations on the pneumococcus and on the current  
12 status of pneumococcal disease and its prevention. Clin Infect Dis. 3 (Supplement  
13  
14 1): S1-S17.  
15  
16  
17

18  
19 8. Coffey T., Enright M., Daniels M., Morona J., Morona R., Hryniewicz W., Paton  
20 J. and Spratt B. (1998). Recombinational exchanges at the capsular  
21 polysaccharide biosynthetic locus lead to frequent serotype changes among  
22 natural isolates of *Streptococcus pneumoniae*. Molecular Microbiology. 27 (1): 73–  
23  
24  
25  
26  
27  
28  
29 83.  
30  
31

32 9. Lysenko E., Lijek R., Brown S. and Weiser J. (2010). Within-Host Competition  
33 Drives Selection for the Capsule Virulence Determinant of *Streptococcus*  
34  
35 *pneumoniae*. Current Biology. 20 (13): 1222-1226.  
36  
37  
38

39  
40 10. Angel S., Ruzek, M. and Hostetter, M. K. (1994). Degradation of C3 by  
41  
42 *Streptococcus pneumoniae*. J Infect Dis 170, 600–608.  
43  
44  
45

46 11. Hyams C., Camberlein E., Cohen J., Bax K. and Brown J. (2010).  
47  
48 The *Streptococcus pneumoniae* Capsule Inhibits Complement Activity and  
49  
50 Neutrophil Phagocytosis by Multiple Mechanisms. Infect. Immun. 78(2): 704-715.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 12. Madden J, Ruiz N. and Caparon M. (2001). Cytolysin-mediated translocation  
4 (CMT): a functional equivalent of type III secretion in gram-positive bacteria. Cell,  
5  
6 104:143–152.  
7  
8

9  
10  
11 13. Lonks J., Garau J., Gomez L., Xercavins M., Echagüen A., Gareen I., Reiss P.  
12 and Medeiros A. (2002). Failure of Macrolide Antibiotic Treatment in Patients with  
13 Bacteremia Due to Erythromycin-Resistant *Streptococcus pneumoniae*. Clin Infect  
14 Dis. 35 (5):556-564.  
15  
16

17  
18 14. Rolston K., Wang W., Neshor I., Coyle E., Shelburne S. and Prince R. (2014).  
19 In vitro activity of telavancin compared with vancomycin and linezolid against  
20 Gram-positive organisms isolated from cancer patients. The Journal of  
21 Antibiotics 67, 505-509.  
22  
23

24  
25 15. Schmitz F., Perdikouli M., Beeck A., Verhoef J. and Fluit A. (2001). Resistance  
26 to trimethoprim–sulfamethoxazole and modifications in genes coding for  
27 dihydrofolate reductase and dihydropteroate synthase in European *Streptococcus*  
28 *pneumoniae* isolates. J Antimicrob Chemother. 48: 935–936.  
29  
30

31  
32 16. Cui Y., Zhao Y., Tian Y., Zhang W., Lü X. and Jiang X. (2012). The molecular  
33 mechanism of action of bactericidal gold nanoparticles on *Escherichia coli*.  
34 Biomaterials. Mar;33(7):2327-33.  
35  
36

37  
38 17. Zhou, Y., Kong, Y., Kundu, S., Cirillo, J.D., & Liang, H. (2012). Antibacterial  
39 activities of gold and silver nanoparticles against *E.coli* and *bacillus* Calmete-  
40 Guerin. J. of Nanobiotech. 10:19.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 18. Lokina S. and Narayanan V. (2013). Antimicrobial and Anticancer Activity of  
4 Gold Nanoparticles Synthesized from Grapes Fruit Extract. Chem. Sci. Trans.  
5 2:S105–S110.  
6  
7  
8  
9  
10  
11 19. Niemirowics K., Swiecicka I., Wilczewska A.Z., Misztalewska I., Kalska-Szostko  
12 B., Bienias K., Bucki R. and Car H. (2014) Gold-functionalized magnetic  
13 nanoparticles restrict growth of *Pseudomonas aeruginosa*. International Journal of  
14 Nanomedicine. 9 2217-2224.  
15  
16  
17  
18  
19  
20  
21 20. Rajeshkumar S., Malarkodi C., Vanaja M., Gnanajobitha G. Paulkumar K.,  
22 Kannan C. and Annadurai G. (2013). Antibacterial activity of algae mediated  
23 synthesis of gold nanoparticles from *Turbinaria conoides*. Pharma Chemica,  
24 5(2):224-229.  
25  
26  
27  
28  
29  
30  
31 21. Lima E., Guerra R., Lara V. and Guzmán A. (2013). Gold nanoparticles as  
32 efficient antimicrobial agents for *Escherichia coli* and *Salmonella typhi*. Chemistry  
33 Central Journal, 7:1-11.  
34  
35  
36  
37  
38  
39 22. Khan A. (2012). Medicine at nanoscale: a new horizon. Int. J. Nanomedicine 7:  
40 2997–2998.  
41  
42  
43  
44  
45 23. Jumaa T., Chasib M., Hamid M., Al-Haddad R. (2014). Effect of the Electric  
46 Field on the Antibacterial Activity of Au Nanoparticles on Some Gram-positive and  
47 Gram-negative Bacteria. Nanoscience and Nanotechnology Research. 2(1): 1-7.  
48  
49  
50  
51 24. Hernández-Sierra J., Ruiz F., Pena D., Martínez-Gutiérrez F., Martínez  
52 A., Guillén A., Tapia-Pérez H. and Castañón G. (2008). The antimicrobial  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 sensitivity of *Streptococcus mutans* to nanoparticles of silver, zinc oxide, and gold.  
4  
5 Nanomedicine. 4(3):237-40.  
6  
7

8  
9 25. Tsuang Y., Sol J., Huang Y., Lu C., Chang W. and Wang C. (2008) Studies of  
10 photokilling of bacteria using titanium dioxide nanoparticles. *Artif. Organs.* 32 (2):  
11 167-74.  
12  
13

14  
15 26. Kundu S. and Liang H. (2008). Polyelectrolyte-mediated non-micellar synthesis  
16 of monodispersed 'aggregates' of gold nanoparticles using a microwave approach.  
17 *Colloids Surf A Physicochem Eng Asp.* 330:143-150.  
18  
19

20  
21 27. Azam A., Ahmed F., Arshi N., Chaman M. and Naqvi A.H. (2009). One step  
22 synthesis and characterization of gold nanoparticles and their antibacterial  
23 activities against *E. coli* (ATCC 25922 strain). *International Journal of Theoretical &*  
24 *Applied Sciences*, 1(2): 1-4.  
25  
26

27  
28 28. Daima H.K., Selvakannan P.R., Shukla R., Bhargava S.K. and Bansal V.  
29 (2013) Fine-Tuning the antimicrobial profile of biocompatible gold nanoparticles by  
30 sequential surface functionalization using polioxometalates and lysine. *PLOS ONE.*  
31 8 e79676.  
32  
33


34  
35 29. Hussain S., Hess K., Gearhart J., Geiss K. and Schlager J. (2005). In vitro  
36 toxicity of nanoparticles in BRL 3A rat liver cells. *Toxicology in Vitro.* 19(7): 975–  
37 983.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 30. Pramanik A., Laha D., Bhattacharya D., Pramanik P. and Karmakar P. (2012).  
4  
5 A novel study of antibacterial activity of copper iodide nanoparticle mediated by  
6  
7 DNA and membrane damage. *Colloids Surf.* 1(96):50-55.  
8  
9  
10  
11 31. Wang S., Lawson R., Ray P. and Yu H. (2011) Toxic effects of gold  
12  
13 nanoparticles on *Salmonella typhimurium* bacteria. *Toxicol. Ind. Health.* 27 (6):  
14  
15 547-54.  
16  
17  
18  
19 32. Feris K., Otto C., Tinker J., Wingett D., Punnoose A., Thurber A., Kongara M.,  
20  
21 Sabetian M., Quinn B., Hanna C. and Rosa D. (2010). Electrostatic Interactions  
22  
23 Affect Nanoparticle-Mediated Toxicity to Gram-Negative Bacterium *Pseudomonas*  
24  
25 *aeruginosa* PAO.. *Langmuir.* 26 (6):4429 a 4436.  
26  
27  
28  
29  
30 33. Turkevich J., Stevenson P., Hillier J. (1951). A study of the nucleation and  
31  
32 growth processes in the synthesis of colloidal gold. *Discuss. Faraday Soc.* 11:55-  
33  
34 75.  
35  
36  
37  
38  
39 34. Hoskins J., Alborn W., Arnold J., Blaszczyk L., Burgett S, Dehoff B., Estrem S.,  
40  
41 Fritz L., Fu D., Fuller W., Geringer C., Gilmour R., Glass J., Khoja H., Kraft A.,  
42  
43 Lagace R., Donald J. Leblanc D., Lee L., Lefkowitz E., Lu J., Matsushima P.,  
44  
45 Mcahren S., Mchenney M., Mcleaster K., Mundy C., Nicas T., Norris F., O'gara M.,  
46  
47 Peery R., Robertson G., Rockey P., Sun P., Winkler M., Yang Y., Young-Bellido  
48  
49 M., Zhao G., Zook C., Baltz R., Jaskunas R., Rosteck P., Skatrud P., and Glass J.  
50  
51 (2001). Genome of the bacterium *Streptococcus pneumoniae* Strain R6. *Journal of*  
52  
53 *Bacteriology*, 183(19):5709–5717.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 35. Tettelin H., Nelson K., Paulsen I., Eisen J., Read T., Peterson S., Heidelberg  
4 J., DeBoy R., Haft D., Dodson R., Durkin A., Gwinn M., Kolonay J., Nelson  
5 W., Peterson J., Umayam L., White O., Salzberg S., Lewis M., Radune  
6 D., Holtzapple E., Khouri H., Wolf A., Utterback T., Hansen C., McDonald L.,  
7 Feldblyum T., Angiuoli S., Dickinson T., Hickey E., Holt I., Loftus B., Yang F., Smith  
8 H., Venter J., Dougherty B., Morrison D., Hollingshead S. and Fraser C. (2001).  
9 Complete genome sequence of a virulent isolate of *Streptococcus pneumoniae*.  
10 Science. 293(5529):498-506.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23 36. Saha B., Bhattacharya J., Mukherjee A., Ghosh A., Santra C., Dasgupta A. and  
24 Karmakar P. (2007). In Vitro Structural and Functional Evaluation of Gold  
25 Nanoparticles Conjugated Antibiotics. Nanoscale Res Lett. 2(12): 614–622.  
26  
27  
28  
29  
30  
31 37. Wu B., Huang R., Sahu M., Feng X., Biswas P. and Tang Y. (2010). Bacterial  
32 responses to Cu-doped TiO<sub>2</sub> nanoparticles. Sci. Total Environ. 408(7):1755–1758.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Fig 1



254x142mm (72 x 72 DPI)


Fig. 2



254x142mm (72 x 72 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Fig.3




254x142mm (72 x 72 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


Fig.4



254x142mm (72 x 72 DPI)


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Fig. 5



254x142mm (72 x 72 DPI)

Fig. 6



254x142mm (72 x 72 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60